Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onradivir
- Development stage
- Unknown
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Onradivir (also known as Onravir or ZSP1273) is an orally active, small-molecule inhibitor of the influenza A virus RNA polymerase basic protein 2 (PB2) subunit. Developed by Raynovent Biotech, onradivir acts by binding to the PB2 cap-binding domain, thereby preventing the 'cap-snatching' mechanism essential for initiating viral transcription and replication. This first-in-class antiviral is approved in China for the treatment of acute uncomplicated influenza A in adults and is under clinical evaluation (NDA/BLA stage) as a pediatric granule formulation.
- Brand names
- Anruiwei安睿威
- Other names
- AngelivirIcoavirOnradivirOnravir昂拉地韦昂拉地韦片昂拉地韦颗粒
02
Targets
PB2-CBD (Influenza A virus PB2 cap-binding domain)PB2 (Influenza PB2)
Beyond the preview
Go deeper on onradivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onradivir.